AI-generated · cited to primary sources · not investment advice · How we research
Marksans Pharma
Our verdict on Marksans Pharma isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
Q1 FY26 R&D spending was exactly 2% of consolidated revenue, aligning with the upper end of the guided range. (3 met across 3 tracked commitments)
“Moving on, we do expect the R&D expenditure to remain between, say, 1.9% to 2% on a year-on-year basis.”
Q1FY26 EBITDA margins dropped significantly to 16.1% compared to 21.7% in Q1FY25 and 20.3% for full year FY25, primarily due to ramp-up costs at the acquired facility and a one-time ECL provision. (1 missed, 4 met across 5 tracked commitments)
“So, I think in next two to three quarters, it should come back to 120-130 days.”
See the full cited Management analysis of Marksans Pharma
How durable is the business?
Operating leverage is expanding as the Unit 2 (Teva) facility ramps up, though margins were temporarily impacted by headcount additions at this site. The facility successfully passed a US FDA inspection with zero observations. (1 expanding)
“Accreditations: USFDA, UK MHRA, Australian TGA, EU and Health Canada.”
The company is aggressively expanding its product pipeline with 58 SKUs commercialized during the year and 79 more products in the pipeline. (2 expanding)
“And during the year, we managed to commercialize 58 SKUs and have about 79 more products in the pipeline.”
See the full cited Business Model analysis of Marksans Pharma
Where does growth come from?
Revenue from the acquired Teva facility is scaling up; while it contributed Rs. 325 Cr in FY25, it is currently trending at a run-rate of Rs. 400-500 Cr for FY26, moving toward the Rs. 1,000 Cr peak capacity target. (5 accelerating across 5 signals, 2 leading indicators)
“No, I mentioned in the next 2 to 3 years is INR 4,000 crores odd, not INR 5,000 crores... Next 2 to 3 years, yes. FY28 or FY29.”
The U.S. order book is showing strong forward momentum, with management projecting an increase to $300 million within two years, despite current geopolitical uncertainties. (1 accelerating, 2 steady across 3 signals)
“Yes. Our order book still stands at a very strong $220 million plus. We are still working towards our objective of going to the next milestone.”
See the full cited Future Growth analysis of Marksans Pharma
What could break the thesis?
The Teva facility integration is progressing but slower than expected; Q4 volumes were 200 million units against a target of 400-500 million. Revenue from the plant was Rs. 325 crores for FY25, below the eventual Rs. 1,000 crore target. (5 intensifying)
“Working capital cycle ~151 days for Q3FY26”
The risk has intensified as the UK market saw 'abnormal' price erosion in the Rx (prescription) segment, which management attributes to a 'cascading effect' of US tariff uncertainties forcing competitors to offload products in the UK. Revenue in the UK/EU segment dropped to INR 203.8 crores from INR 258.2 crores previously. (1 intensifying, 4 easing, 1 high-severity)
“US & North America ₹ 412.4 cr (54.7%) | UK & Europe ₹ 258.2 cr (34.2%)”
See the full cited Risk analysis of Marksans Pharma
Read the full thesis on Marksans Pharma
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.